Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials
10.1097/HJH.0b013e328341939d
Diabetes 52(2):380386 Lau J, Bloch P, Schffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM (2015) Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Glucagon-like peptide-1 (GLP-1) is an incretin hormone, one of several gut-derived peptides secreted in response to nutrient intake that promote insulin release
These effects contribute to weight loss that varies by agent and dosetypically ranging from 5-8% with liraglutide 3 mg (Saxenda), up to 15% with semaglutide 2.4 mg (Wegovy), and potentially up to 20% with higher doses of tirzepatide (Zepbound)
While this medication remains branded, its use will be limited by its cost